Indian J Med Res 158, July 2023, pp 5-16 DOI: 10.4103/ijmr.ijmr\_1946\_21

# **Systematic Review**



Role of calcium &/or vitamin D supplementation in preventing osteoporotic fracture in the elderly: A systematic review & meta-analysis

Kavin Khatri<sup>1</sup>, Manmeet Kaur<sup>2</sup>, Tanish Dhir<sup>4</sup>, Ankita Kankaria<sup>3</sup> & Hobinder Arora<sup>5</sup>

Departments of <sup>1</sup>Orthopaedics, <sup>2</sup>Pathology & <sup>3</sup>Community & Family Medicine, All India Institute of Medical Sciences, Bathinda, <sup>4</sup>Department of Nephrology, Dayanand Medical College & Hospital, Ludhiana & <sup>5</sup>Department of Community & Family Medicine, Guru Gobind Singh Medical College, Faridkot, Punjab, India

Received June 23, 2021

*Background & objectives*: Calcium and vitamin D, separately or in combination are usually prescribed to prevent fragility fractures in elderly population. However, there are conflicting results regarding the ideal dosage and overall efficacy obtained from randomized controlled trials (RCTs) conducted in the past. The objective of this study was to assess the fracture risk with the administration of calcium or vitamin D alone or in combination in elderly population (>60 yr).

*Methods*: PubMed, Cochrane and Embase databases were searched to identify the studies from inception to February 2021 with keywords, 'vitamin D', 'calcium' and 'fracture' to identify RCTs. The trials with comparing vitamin D, calcium or combination with either no medication or placebo were included for final analyses. The data were extracted and the study quality was assessed by two reviewers. The principal outcome measure was fractures around hip joint and secondary outcomes assessed were vertebral and any other fracture.

*Results*: Eighteen RCTs were considered for the final analysis. Neither calcium nor vitamin D supplementation was associated with risk of fractures around hip joint [risk ratio (RR) 1.56; 95% confidence interval (CI), 0.91 to 2.69, P=28%; P=0.11]. In addition, the combined administration of calcium and vitamin D was also not associated with fractures around the hip joint in comparison to either no treatment or placebo. The incidence of vertebral (RR 0.95; 95% CI, 0.82 to 1.10, P=0%; P=0.49) or any other fracture (RR 0.83; 95% CI 0.65 to 1.06, P=0%; P=0.14) was not significantly associated with the administration of calcium and vitamin D either individually or in combination. Further subgroup analysis of the results did not vary with the dosage of calcium or vitamin D, dietary calcium intake sex, or serum 25-hydroxyvitamin D levels.

*Interpretation & conclusions*: The present meta-analysis of RCTs on calcium, vitamin D or a combination of the two in comparison to no treatment or placebo did not support the routine administration protocol of calcium and vitamin D either alone or in combination to lower the risk of fractures in elderly population.

Key words 25-Hydroxyvitamin D - calcium - hip fracture - osteoporosis - risk - randomized controlled trials - vitamin D

With the rise in the elderly population worldwide, the incidence of osteoporotic fractures is increasing proportionately<sup>1</sup>. Reportedly, there is a probability that approximately 50 per cent women and 20 per cent men aged 50 yr suffer an osteoporotic fracture in their remaining lifetime<sup>2,3</sup>. Hip fracture is one among the most serious types of fragility fractures with approximately one third risk of death in the subsequent year<sup>4</sup>. The survivors require good nursing and social care which translates into a major social and economic burden<sup>5</sup>. Hence, the thrust should be on prevention of these fractures. Common practice is to recommend combined calcium and vitamin D supplements to patients after an osteoporotic fracture to prevent chances of the same in the future. Vitamin D is required for the maintenance of good musculoskeletal health as it promotes the absorption of calcium, osteoid mineralization and maintenance of muscle functions.

Previous studies on the effect of calcium supplementation on bone density have demonstrated that there is no substantial increase in bone density beyond one year of calcium administration<sup>6,7</sup>. Moreover, the influx of calcium ions in the blood leads to suppression in the parathyroid hormone levels, thus affecting the cycle of bone resorption and formation<sup>8</sup>. Few observational studies in the past have also shown that there is no relationship between calcium intake and risk of fracture<sup>9</sup>. The regions with low calcium intake touching Asia and Africa have a lower incidence of fracture in comparison to Europe and North America. This phenomenon has been referred to as the 'Calcium Paradox'. In published literature, there is no consensus to support the use of either calcium alone or in combination with vitamin D to reduce the risk of subsequent fractures. Hence, this meta-analysis was planned to assess calcium and, vitamin D individually or in combination administration of calcium and vitamin D with placebo for fracture incidence in the elderly population.

### **Material & Methods**

This systematic review and meta-analysis was performed as per the recommendations of the PRISMA statement<sup>10</sup> and was registered in PROSPERO (CRD 42021218539).

Search strategy: PubMed, EMBASE and COCHRANE databases were searched since inception to February 2021, to collect information on published trials for evaluating the association between calcium and, vitamin D (individually or in

combination) supplementation on the incidence of fractures in elderly individuals with a prior history of a fracture. In addition, *clinicaltrials.gov* was also searched for any undergoing trials. The keywords searched were 'calcium', 'vitamin D', and 'fracture'. No restriction of language, date or publication status was applied on the search. The bibliographic details of all the included studies were searched manually for any additional citations. In case of duplication of publication, the study with the entire data set was excluded. The complete search strategy has been listed in the Supplementary Material.

*Inclusion criteria*: Randomized controlled trials (RCTs) or meta-analyses comparing calcium, and vitamin D, individually or in or combination administered either with placebo or no treatment were included in this study. Furthermore, this studies included adults older than 50 yr with a previous history of fracture.

*Exclusion criteria*: Studies without a treatment or placebo group, with individuals having glucocorticoid-associated osteoporosis, employed co-administration of calcium and, vitamin D individually or in combination with other treatment modalities like antiresorptive medication or included of dietary supplementation of either calcium or vitamin D were excluded from this study.

Selection of study data and data extraction: All the studies were independently screened for meeting the study criteria using Rayyan web application<sup>11</sup>. In case of any disagreement regarding the inclusion of the study, the matter was resolved by a third author. The reviewers independently extracted the characteristics of the studies and outcome measures. The extraction form was developed as per Cochrane recommendations<sup>12</sup>. Any discrepancy between the data extracted twice was resolved by analysis of the full text by all the reviewers. The patient characteristics, calcium and, vitamin D administered individually or in combination, dicalcium intake, serum vitamin D levels, cases with a history of hip, vertebral or nonvertebral fracture along with the duration of the trial were recorded.

Assessment of risk of bias: Cochrane Collaboration's tool was used to check for the quality of studies included for the meta-analysis<sup>13</sup>. Each study was checked for random generation of sequence; reporting of selective outcome; concealment of allocation; blinding of participants; incomplete outcome data; selective outcome reporting and potential sources of bias like



Fig. 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram for the study inclusion and exclusion procedure.

conflicts of interest. The performance of each study was checked for risk of bias and tabulated. The risk of bias was categorized as low, medium and high risk. When either randomization or allocation concealment was assessed as a high risk of bias regardless of other items, the trials were considered as low quality. Similarly, when both randomization and allocation concealment was assessed as a low risk of bias and other items as low or unclear risk of bias, the trial was considered as high quality. The trials which did not meet high or low quality criteria were considered as moderate quality<sup>14,15</sup>. A study was labelled with low risk of bias if six out of the seven chosen domains were found to be low risk<sup>12</sup>.

*Statistical analysis*: The incidence of fracture was assessed for association with calcium and, vitamin D, administration individually or in combination. Each component was also compared with a placebo or treatment given in the studies. The meta-analysis was performed to obtain relative risk ratios, absolute risk difference and 95% confidence interval. In cases where relative risk and absolute risk difference lead to similar end result, the results of relative risk were taken into consideration, especially when an intervention was targeted to prevent an unwanted event<sup>16</sup>.

The random-effect model of derSimonian and Laird approach<sup>17</sup> was used to estimate pooled RRs and

mean differences with the inverse variance approach. In case of no event in a group, the RR was estimated by adding 0.5 to each cell. The testing of heterogeneity was carried out using Chi-squared test and quantified using P. In the case of P>50 per cent, substantial heterogeneity was considered. P<0.10 was considered significant.

To evaluate the association of fracture with the variables under interest, the subgroups were specified based on dosage with the frequency of calcium supplementation, sex, dietary intake and baseline serum vitamin D levels. The subgroups were analyzed to look for significant results (P<0.05). Funnel plots were used to assess publication bias when the number of trials reporting the primary outcomes was  $\geq 10$ . The statistical analyses were performed using Review Manager Software (Cochrane Collaboration, UK). The criteria mentioned in Cochrane Handbook were used to convert medians, standard errors and 95 per cent CI to means and standard deviations.

#### Results

*Literature search*: A total of 1273 articles were obtained in the initial search for published RCTs on the study topic. Of these, 32 duplicate articles were removed, leaving 1241 for screening. After screening titles and abstracts, 46 full text articles remained for review and 18 articles were included as per the criteria. Hence, a

		Table I. Charac	teristics of inclu	ded randomized controlled tri	als and participants			
Study	Country	Total number of participants	Male:female ratio	Intervention	Comparator	Mean age (yr)	Calcium intake (mg/day)	Serum vitamin D
Hansson and Roos et al <sup>18</sup> , 1987	Sweden	50	0:50	1 g/d calcium (n=25)	Placebo (n=25)	65.9	NA	NA
Reid et al <sup>19</sup> , 1993	New Zealand	135	0:135	1 g/d calcium (n=25)	Placebo (n=67)	58	750	37.5
Recker et al <sup>20</sup> , 1996	United States	197	0:197	1.2 g/d calcium (n=135)	Placebo (n=102)	73.5	434	25.5
Peacock <i>et al</i> <sup>21</sup> , 2000	United States	261	74:187	0.75 g/d (n=126)	Placebo (n=102)	73.8	597	25
Avenell <i>et al</i> <sup>22</sup> , 2004	United States	105	53:11	1 g/d calcium (n=35); 800 IU/day	No treatment (n=35)	78	NA	NA
Harwood <i>et al</i> <sup>23</sup> , 2004	United Kingdom	75	0:75	3,000,000 IU single dose (n=38)	No treatment (n=37)	80.5	NA	11.6
Porthouse <i>et al</i> <sup>24</sup> , 2005	United Kingdom	3314	0:3314	1 g/d calcium (n=1321); 800 IU/day	No treatment (n=1993)	76.8	1080	NA
Grant <i>et a</i> $l^{25}$ , 2005	United Kingdom	2643	402:2241	1 g/d calcium (n=1311); 800 IU/day	Placebo (n=1332)	77	NA	15.2
Prince <i>et al</i> <sup>26</sup> , 2006	Australia	1460	0:1460	0.48 g/d calcium (n=730)	Placebo (n=730)	75.2	915	31
Reid <i>et al</i> <sup>27</sup> , 2006	New Zealand	1471	0:1471	1 g/d calcium (n=732)	Placebo (n=739)	74.3	857	20.7
Jackson <i>et al</i> <sup>28</sup> , 2006	United States	7972	0:7972	1 g/d calcium (n=4015); 400 IU/day	Placebo (n=3957)	62.4	1151	18.9
Smith <i>et al</i> <sup>29</sup> , 2007	United Kingdom	9440	4354:5086	3,000,000 IU single dose (n=4727)	Placebo (n=4713)	79.1	625	22.6
Sander's <i>et al</i> <sup>30</sup> , 2010	Australia	2258	0:2258	5,000,000 IU every year (n=1131)	Placebo (n=1127)	76.1	976	19.8
Salvovaara <i>et al</i> <sup>51</sup> , 2010	Finland	3432	0:3432	1 g/d calcium (n=1718); 800 IU/day	No treatment (n=1714)	67.3	957	19.8
Punthakee <i>et al</i> <sup>32</sup> , 2012	Canada	1221	722:499	1000 IU/day (n=607)	Placebo (n=614)	66.6	NA	NA
Hin <i>et al</i> <sup>33</sup> , 2017	United Kingdom	305	155:150	4000 IU/day (n=102); 2000 IU/day (n=102)	Placebo (n=101)	71.7	710	20.1
Khaw <i>et al</i> <sup>34</sup> , 2017	New Zealand	5108	2969:2139	2,000,000 IU single dose followed by 1,00,000 monthly (n=2558)	Placebo (n=2550)	65.9	810	25.2
Xue <i>et al</i> <sup>35</sup> , 2017	China	312	0:312	0.6 g/d calcium (n=139); 800 IU/day	Placebo (n=173)	63.6	NA	30.8
NA, not available								

INDIAN J MED RES, JULY 2023

8

	Calci	um	No treatment	t or placebo	Weight	Risk ratio		Risk ratio	
Study or Subgroup	Events	Total	Events	Total	(%)	M-H, random, 95%	CI	M-H, random, 95% CI	
1.4.1 hip freture									
Reid et al19, 1993	0	68	2	67	0.2	0.20 [0.01, 4.03]	+		
Avenell et al <sup>22</sup> , 2004	1	29	1	35	0.2	1.21 [0.08, 18.46]	8	· · · ·	45
Grant et al25, 2005	49	1311	41	1332	9.3	1.21 [0.81, 1.83]		-	
Prince et al <sup>26</sup> , 2006	11	730	6	730	1.7	1.83 [0.68, 4.93]		· · · ·	
Reid et al27, 2006	17	732	5	739	1.6	3.43 [1.27, 9.26]			
Subtotal (95% CI)		2870		2903	13	1.56 [0.91, 2.69]			
Total events	78		55						
Heterogeneity $Tau^2 = 0.11$ ; (	$Chi^2 = 5.53$	3; df = 4	$(P=0.24); I^2$	= 28%					
Test for overall effect: $Z = 1$	.60 ( <i>P</i> =0.	11)							
1.4.2 vertebral factors									
Reid et al19, 1993	2	68	6	67	0.7	0.33 [0.07, 1.57]	-		
Peacock et al <sup>21</sup> , 2000	11	119	12	117	2.7	0.90 [0.41, 1.96]			
Avenell et al <sup>22</sup> , 2004	4	29	3	35	0.8	1.61 [0.39, 6.62]		<u> </u>	
Grant et al25, 2005	163	1311	178	1332	33.2	0.93 [0.76, 1.13]		+	
Reid et al27, 2006	107	732	109	739	23.1	0.99 [0.77, 1.27]		+	
Subtotal (95% CI)		2259		2290	60.5	0.95 [0.82, 1.10]		+	
Total events	287		308						
Heterogeneity $Tau^2 = 0.00$ ; Test for overall effect: $Z = 0$	$Chi^2 = 2.43$ 0.70 ( $P=0.4$	8; df = 4 49)	(P=0.65); I <sup>2</sup>	e = 0%					
1.4.3 other factors									
Hansson and Ross18, 1987	1	25	1	25	0.2	1.00 [0.07, 15.12]	_		_
Reid et al19, 1993	0	68	1	67	0.2	0.33 [0.01, 7.92]			
Recker et al20, 1996	27	95	34	102	8.7	0.85 [0.56, 1.30]			
Peacock et al <sup>21</sup> , 2000	7	126	13	135	2.1	0.58 [0.24, 1.40]			
Avenell et al <sup>22</sup> , 2004	0	29	1	35	0.2	0.40 [0.02, 9.46]			
Grant et al25, 2005	3	1311	1	1332	0.3	3.05 [0.32, 29.26]		<u> </u>	
Reid <i>et al</i> <sup>27</sup> . 2006	27	730	38	739	6.7	0.72 [0.44, 1.17]			
Prince <i>et al</i> <sup>26</sup> , 2006	38	730	39	730	8.2	0.97 [0.63, 1.51]		+	
Subtotal (95% CI)		3114	57	3165	26.6	0.83 [0.65, 1.06]			
Total events	103		128						
Heterogeneity $Tau^2 = 0.00$ ;	$Chi^2 = 3.3$	4; df = 7	(P=0.85); I <sup>2</sup>	2 = 0%					
Test for overall effect: $Z = 1$	.49 ( <i>P</i> =0.	14)							
Total (95% CD)				8358	100	0 96 [0 85 1 10]			
Totsl events	468			0550	100	0.90 [0.00, 1.10]			
Heterogeneity $Tau^2 = 0.00$ .	$Chi^2 = 17$	$54 \cdot df =$	17 (P=0.42)	$I^2 = 3\%$			<b> </b>	· · · · · ·	
Test for overall effect: $Z = 0$	0.55 (P=0.4	58)	(	,- 0,0			0.01 0.	1 1 10	100
Test for subgroup difference	s: Chi <sup>2</sup> = 4	4.32; df -	= 2 (P=0.12)	; $I^2 = 53.7\%$			Favou	rs calcium Favours no	treat/placebo

#### KHATRI et al: CALCIUM OR VITAMIN D SUPPLEMENTATION IN THE ELDERLY

Fig. 2. Forrest plot of trials with administration of calcium for prevention of fracture in hip, vertebrae and other parts of the body.

total of 18 RCTs which involved 39759 participants were selected in this meta-analysis (Fig. 1). The characteristics of the included RCTs are given in Table I and the list of excluded trials along with the reasons have been provided in the Supplementary Table.

The risk of bias of the studies included was assessed (Supplementary Figs 1 and 2). Egger's linear regression analysis was used for the evaluation of publication bias for the primary outcome measure and no publication bias was noted (P=0.901; Supplementary Fig. 3). Calcium intake and risk of fracture: Calcium was administered in the form of calcium carbonate in ten trials, calcium citrate malate in two trials, calcium citrate in two trials; combination of bicarbonate, lactate and, gluconate in one trial; lactate, gluconate, carbonate in two trials and unclear form in one trial. The association between calcium administration and hip fracture [risk ratio (RR) 1.56; 95% confidence interval (CI), 0.91 to 2.69, P=28%; P=0.11], vertebral fracture (RR 0.95; 95% CI, 0.82 to 1.10, P=0%; P=0.49) or

Table II. Subgroup analysis for cal	cium administration and	fracture risk preventio	n in each factor	
Factor	Participants with fracture	Total number of participants	RR (95% CI)	Р
	Hip fracture			
Dose of calcium				
<1 g	17	1460	1.83 (0.68-4.93)	0.76
>1 g	116	4313	1.51 (0.67-3.37)	
Sex				
Women only	41	3066	1.97 (0.74-5.28)	0.31
Both sex	92	2707	1.21 (0.81-1.82)	
Serum 25(OH)D levels at presentation				
>20 ng/ml	41	3066	1.97 (0.74-5.28)	0.16
<20 ng/ml	92	2707	1.21 (0.81-1.82)	
	Vertebral fracture			
Dose of calcium				
>1 g	572	4313	0.95 (0.82-1.11)	0.63
<1 g	23	236	0.90 (0.41-1.96)	
Sex				
Women only	224	1606	0.76 (0.30-1.92)	0.94
Both sex	371	2943	0.94 (0.78-1.13)	
Serum 25(OH)D levels at presentation				
>20 ng/ml	247	1842	0.96 (0.76-1.21)	0.76
<20 ng/ml	341	2643	0.93 (0.76-1.13)	
	Other fracture			
Dose of calcium				
>1 g	158	1918	0.87 (0.65-1.15)	0.56
<1 g	73	4361	0.75 (0.47-1.18)	
Sex				
Women only	204	3261	0.85 (0.66-1.09)	0.97
Both sex	28	3153	0.68 (0.32-1.44)	
Serum 25(OH)D levels at presentation				
>20 ng/ml	143	3064	0.84 (0.61-1.16)	0.84
<20 ng/ml	85	3101	0.82 (0.57-1.20)	
25(OH)D, 25-hydroxy vitamin D; CI, confidence inter	val; RR, relative risk			

other fractures (RR 0.83; 95% CI 0.65 to 1.06, P=0%; P=0.14) was not significant (Fig. 2) in comparison to either no treatment or placebo administration. The subgroup analysis was carried out for the assessment of fracture risk in the hip, vertebra and other parts of the body, but there was no significant association based on calcium dosage, sex and serum 25-hydroxy vitamin D [25OH)D] levels (Table II).

<u>Vitamin D intake and risk of fracture</u>: Vitamin D supplementation with a placebo or no treatment was compared in six trials. The association between

vertebral fracture (RR, 1.28; 95% CI, 0.80 to 2.05, P=0%; P=0.31), hip fracture (RR, 1.18; 95% CI, 0.91 to 1.53, P=0%; P=0.21), or other fracture (RR, 1.09; 95% CI, 0.94 to 1.20, P=0%; P=0.11; Fig. 3) was not found to be significant. The subgroup analysis for different dosage and frequency of assessment of fracture risk was not found to be significantly associated (Table III).

Combined vitamin D and Calcium administration and fracture risk: Supplementation of calcium and

	Vitam	in D N	o treatment	t or placebo	Weight	Risk ratio	Ri	sks ratio	
Study or Subgroup	Events	Total	Events	Total	(%)	M-H, random, 95% C	M-H, rai	ndom, 95% CI	
1.1.1 hip freture									
Avenell et al <sup>22</sup> , 2004	0	35	1	35	0.1	0.33 [0.01, 7.91]	•		
Harwood et al <sup>23</sup> , 2004	0	38	1	37	0.1	0.32 [0.01, 7.73]	1. S.I.		
Grant et al <sup>25</sup> , 2005	47	1343	41	1332	6.7	1.14 [0.75, 1.72]		·-	
Smith et al <sup>29</sup> , 2007	55	4727	44	4713	7.4	1.25 [0.84, 1.85]			
Sanders et al30, 2010	19	1131	15	1127	2.5	1.26 [0.64, 2.47]			
Subtotal (95% CI)		7274		7244	16.9	1.18 [0.91, 1.53]			
Total events	121		102						
Heterogeneity $Tau^2 = 0.0$ Test for overall effect: Z	0; $Chi^2 = 1$ = 1.26 ( <i>P</i> =	1.39; df = =0.21)	4 ( <i>P</i> =0.85)	); $I^2 = 0\%$					
1.1.2 vertebral factors									
Avenell et al <sup>22</sup> , 2004	0	35	1	35	0.1	0.33 [0.01, 7.91]	· · · · ·		
Grant et al <sup>25</sup> , 2005	4	1343	1	1332	0.2	3.97 [0.44, 35.45]	-		
Sanders et al30, 2010	35	1131	28	1127	4.8	1.25 [0.76, 2.03]		±	
Subtotal (95% CI)		2509		2494	5.1	1.28 [0.80, 2.05]		•	
Total events	39		30						
Heterogeneity $Tau^2 = 0.0$ Test for overall effect: Z	0; $Chi^2 = 1$ = 1.01 ( <i>P</i> =	1,73; df = =0.31)	2 (P=0.42)	); $I^2 = 0\%$					
1.1.3 other factors									
Avenell et al <sup>22</sup> , 2004	3	35	3	35	0.5	1.00 [0.22, 4.62]			
Grant et al <sup>25</sup> , 2005	165	1343	178	1332	29.3	0.92 [0.75, 1.12]		4	
Smith et al29, 2007	55	4727	44	4713	7.4	1.25 [0.84, 1.85]		1-	
Sanders et al30, 2010	124	1131	101	1127	18.4	1.22 [0.95, 1.57]			
Hin et al <sup>33</sup> , 2017	6	204	1	101	0.3	2.97 [0.36, 24.34]	-	· · · · ·	
Khaw et al34, 2017	146	2558	136	2550	22.2	1.07 [0.85, 1.34]		* ·	
Subtotal (95% CI)		9998		9858	78	1.06 [0.94, 1.20]		•	
Total events	499		463						
Heterogeneity $Tau^2 = 0.00$ Test for overall effect: Z	0; Chi <sup>2</sup> = $4^{2}$ = 0.97 ( <i>P</i> =	4.85; df = =0.33)	5 (P=0.43)	); $I^2 = 0\%$					
Total (95% CI)		19781		19596	100	1.09 [0.98, 1.21]		•	
Hotorogonaity $T_{av}^2 = 0.0$	0. $C_{1}^{12} = 0$	2 06. 4F-	12 (D-0 7	8). $R = 00^{7}$			5		
Therefore a control of the fraction $T_{\rm eff} = 0.0$	-1.60 ( <i>p</i> -	5.90; uI = -0.11)	- 13 ( <i>P</i> =0.7	$0), I^2 = 0\%$			0.01 0.1	1 10 10	
Test for overall effect: Z	- 1.00 (P=	-0.11)		(1) 72 000			Favours vitamin D	Favoure no treat/place	ebo
Test for subgroup differe	nces: Chi <sup>2</sup>	=0.98; d	t = 2 (P=0.0)	$(51); I^2 = 0\%$	D			r avours no neat/plac	-00

Fig. 3. Forrest plot of trials with the administration of vitamin D for prevention of fracture in hip, vertebrae and other parts of the body.

vitamin D combined versus placebo or no treatment was compared in seven trials. The association between vertebral fracture (RR, 0.63; 95% CI, 0.29 to 1.40, P=0%; P=0.26), hip fracture (RR, 1.10; 95% CI, 0.86 to 1.40, P=0%; P=0.47) and other fractures (RR, 0.921; 95% CI, 0.78 to 1.08, P=0%; P=0.29; Fig. 4) was not found to be significant. There was no significant difference in the subgroup analysis based on intake of calcium and vitamin D, sex, baseline 25(OH)D levels and dietary intake of calcium (Table IV).

#### Discussion

The meta-analysis revealed that calcium and, vitamin D individually or in combination did not

lower the chances of hip, vertebral or any other fragility fractures in the elderly population. The exclusion of low-quality trials and trials with patients using specific medication did not affect the results. The outcome was independent of calcium, vitamin D dosage or the combination of two, sex and serum 25(OH)D levels.

Prior meta-analysis carried out by Tang *et*  $al^{36}$  had reported decrease in fragility fractures with calcium supplementation. However, they had included two cluster trials<sup>15,16</sup> with a large sample size and did not adjust for the cases which could have increased the chance of achieving low *P* value

Factor	Participants	Total	RR (95% CI)	Р
	with fracture	number of participants		
	Hip fracture	1 1		
Frequency of vitamin D supplementation	•			
Low daily dose	89	2745	1.11 (0.74-1.68)	0.17
High dose once yearly	35	2333	1.19 (0.62-2.3)	
High dose intermittently	99	9440	1.25 (0.84-1.85)	
Sex				
Women only	34	2258	1.26 (0.64-2.47)	0.52
Both sex	89	2745	1.11 (0.74-1.68)	
Serum 25(OH)D levels at presentation				
>20 ng/ml	222	14,448	1.19 (0.92-1.55)	NA
<20 ng/ml	0	0	NA	
	Vertebral fracture			
Frequency of vitamin D supplementation				
Low daily dose	6	2745	1.51 (0.14-16.14)	0.21
Intermittent high dose	63	2258	1.25 (0.76-2.03)	
Sex				
Women only	63	2258	1.25 (0.76-2.03)	0.49
Both sex	6	2745	1.51 (0.14-16.14)	
Serum 25(OH)D levels at presentation				
>20 ng/ml	0	0	NA	NA
<20 ng/ml	69	5003	1.28 (0.80-2.05)	
	Other fracture			
Frequency of vitamin D supplementation				
Low daily dose	349	2745	0.92 (0.76-1.12)	0.23
High dose once yearly	225	2258	1.22 (0.95-1.57)	
High dose intermittently	282	5108	1.07 (0.85-1.34)	
Sex				
Women only	225	2258	1.22 (0.95-1.57)	0.56
Both sex	730	17,293	1.01 (0.88-1.16)	
Serum 25(OH)D levels at presentation				
>20 ng/ml	955	19551	1.09 (0.98-1.21)	NA
<20 ng/ml	0	0	NA	
CI, confidence interval; NA, not available; RR, rel	ative risk			

and narrow confidence intervals in the comparison groups. In another meta-analysis by Bolland *et al*<sup>9</sup>, the dietary intake of calcium did not decrease the risk of fracture, and role of calcium supplementation in the prevention of fracture was also doubtful. In the present study, no association between calcium supplementation and the risk of fracture was observed. Hence, calcium supplementation need not be a routine recommendation for lowering risk of fracture.

A meta-analysis by Bischoff-Ferrari *et al*<sup>37</sup> had reported lower chances of hip fracture and other fragility fractures with the use of a high dose of vitamin D ( $\geq$ 800 IU) per day. The inclusion of institutional patients by Chapuy *et al*<sup>38</sup> in the metaanalysis could have affected the finding of the meta-

|--|

	Calciu	um with	Vitamin D	No treatment	or placebo	Weight	Risk ratio	Risks ratio
Study or Subgroup	F	Events	Total	Events	Total	(%)	M-H, random, 95% C	CI M-H, random, 95% CI
1.2.1 hip fracture								
Avenell et al <sup>22</sup> , 2004		1	35	1	35	0.2	1.00 [0.07, 15.36]	
Harwood et al <sup>23</sup> , 2004	1	1	75	1	37	0.2	0.49 [0.03, 7.67]	
Porthouse et al <sup>24</sup> , 200	5	8	1321	17	1993	2.6	0.71 [0.31, 1.64]	
Grant et al <sup>25</sup> , 2005		46	1306	41	1332	10.5	1.14 [0.76, 1.73]	
Jackson et al <sup>28</sup> , 2006		70	4015	61	3957	15.5	1.13 [0.80, 1.59]	
Salvovaara et al <sup>31</sup> , 20	10	4	1718	2	1714	0.6	2.00 [0.37, 10.88]	•
Subtotal (95% CI)			8470		9068	29.6	1.10 [0.86, 1.40]	ľ
Total events		130		123				
Heterogeneity Tau <sup>2</sup> = Test for overall effect	0.00; 0 :: Z = 0	Chi <sup>2</sup> = 1. .73 ( <i>P</i> =0	92; df = 5 ( ).47)	$P=0.86$ ; $I^2 =$	0%			
1.2.2 vertebral factors	s							
Avenell et al <sup>22</sup> , 2004		0	35	1	35	0.2	0.33 [0.01, 7.91]	· · · · · · · · · · · · · · · · · · ·
Grant et al25, 2005		0	1306	1	1332	0.2	0.34 [0.01, 8.34]	, , , , , , , , , , , , , , , , , , , ,
Jackson et al28, 2006		9	1718	13	1714	2.5	0.69 [0.30, 1.61]	
Subtotal (95% CI)			3059		3081	2.9	0.63 [0.29, 1.40]	
Total events		9		15				
Heterogeneity Tau <sup>2</sup> = Test for overall effect	0.00; C :: $Z = 1$	$Chi^2 = 0.1$ .14 ( $P=0$	34; df = 2 ( .26)	$P=0.84$ ; $I^2 =$	0%			
1.2.3 other factors								
Harwood et al <sup>23</sup> , 2004	1	6	75	5	37	1.4	0.59 [0.19, 1.81]	
Avenell et al <sup>22</sup> , 2004		2	35	3	35	0.6	0.67 [0.12, 3.75]	
Grant et al25, 2005		165	1306	178	1332	45.9	0.95 [0.78, 1.15]	+
Smith et al29, 2007		2	62	44	61	0.5	0.98 [0.14, 6.76]	
Salvovaara et al <sup>31</sup> , 20	10	71	1718	101	1714	18.6	0.86 [0.63, 1.18]	-
Xue et al33, 2017		3	139	1	173	0.6	1.87 [0.32, 11.02]	
Subtotal (95% CI)			3335		3352	67.6	0.92 [0.78, 1.08]	•
Total events		249		463				
Heterogeneity Tau <sup>2</sup> =	0.00; 0	$Chi^2 = 1.2$	57; $df = 5$ (	$P=0.90); I^2 =$	0%			
Test for overall effect	: Z = 1	.06 (P=0	).29)					
Total (95% CI)			14864		15501	100	0.96 [0.84, 1.09]	L
Total events								Ţ
Heterogeneity Tau <sup>2</sup> =	0.00; 0	$Chi^2 = 6.3$	32; df = $14$	(P=0.96); I <sup>2</sup> =	- 0%			
Test for overall effect	: Z = 0.	.67 (P=0	.51)					0.01 0.1 1 10 100
Test for subgroup diff	ference	s: Chi² =	2.49; df = 2	2 (P=0.29); P	= 19.8%		Favo	urs calcium+vitamin D Favours no treat/place

Fig. 4. Forrest plot of trials with the combined administration of calcium and vitamin D for prevention of fracture in hip, vertebrae and other parts of the body.

analysis. Other meta-analyses by Bergman *et al*<sup>39</sup> supported the use of a high dose of vitamin D to prevent the non-vertebral and non-hip fragility fractures. However, they reported no significant association between high dose vitamin D and hip fractures. In the present study, the reason for the difference in the result could be due to reporting of neutral or negative association between vitamin D administration and risk of fracture.

In a Cochrane review by Avenell *et al*<sup>40</sup>, the chance of hip fracture or combined fragility fracture was suggestively reduced with the combined administration of calcium and vitamin D. In contrast, Bolland *et al*<sup>41</sup> reported no beneficial effect with the administration of calcium and vitamin D in combination in osteoporotic fractures. A meta-analysis by Zhao *et al*<sup>14</sup> reported inconsistent results with a combined supplementation of calcium and vitamin D due to different inclusion criteria like the restriction of RCTs to community dwellers or residents of nursing homes.

In a study by Jackson *et al*<sup>42</sup>, positive interaction was reported between hormonal therapy and calcium and vitamin D supplementation. They concluded that a lower risk of fragility fractures with this combination was found in individuals on hormonal therapy in contrast to the study group not on

Table IV. Subgroup analysis with combined ca	alcium and vitamin D	administration for fra	acture risk prevention	
Factor	Participants with fracture	Total number of participants	RR (95% CI)	Р
	Hip fracture			
Combined calcium and vitamin D supplementation				
Calcium with >1 g with low daily vitamin D	120	9454	1.07 (0.75-1.54)	0.83
Other	133	8084	1.12 (0.80-1.57)	
Sex				
Women only	164	14,830	1.07 (0.79-1.46)	0.81
Both sex	89	2708	1.14 (0.76-1.72)	
Serum 25(OH)D levels at presentation				
>20 ng/ml	0	0	NA	NA
<20 ng/ml	251	17,468	1.10 (0.86-1.4)	
	Vertebral fracture			
Combined calcium and vitamin D supplementation				
Calcium with >1 g with low daily vitamin D	2	2708	0.34 (0.04-3.2)	0.67
Other	22	3432	0.69 (0.30-1.61)	
Sex				
Women only	22	3432	0.69 (0.30-1.61)	0.45
Both sex	2	2708	0.34 (0.04-3.2)	
Serum 25(OH)D levels at presentation				
>20 ng/ml	0	0	NA	NA
<20 ng/ml	24	6140	0.63 (0.29-1.4)	
	Other fracture			
Combined calcium and vitamin D supplementation				
Calcium with >1 g with low daily vitamin D	512	6252	0.91 (0.77-1.07)	0.53
Other	4	123	0.98 (0.14-6.76)	
Sex				
Women only	15	235	0.67 (0.26-1.77)	0.51
Both sex	501	14,988	0.92 (0.78-1.08)	
Serum 25(OH)D levels at presentation				
>20 ng/ml	0	0	NA	NA
<20 ng/ml	516	6375	0.91 (0.77-1.07)	
CI, confidence interval; NA, not available; RR, relative ris	k			

hormonal therapy which did not report any reduction in fracture risk. In the present meta-analysis, all the cases on hormonal therapy were excluded from the analysis.

The data from VITAL trial<sup>43</sup> reported that vitamin D3 supplementation did not reduced risk of fractures.

There is a requirement of a large RCTs, especially in elderly high risk individuals involving combined administration of calcium and vitamin D to obtain a reliable evidence. The present study did have a few limitations. First, some studies did not include the baseline values of 25(OH)D levels which could have altered the results of the subgroup analysis. Second, few RCTs were of poor quality with allocation bias. Third, there are chances of publication bias in the results reported by individual RCTs. Fourth, there could have been variations in the classification of quality of the studies.

Overall, the present meta-analysis involving RCTs that included calcium and, vitamin D administered

individually or in combination compared with either no treatment or placebo do not support their routine supplementation in the elderly population. However, the results of undergoing RCTs involving high doses of vitamin D may have bearing on the future metaanalyses.

### Financial support & sponsorship: None.

#### Conflicts of Interest: None.

#### References

- 1. Sambrook P, Cooper C. Osteoporosis. *Lancet* 2006; *367* : 2010-8.
- Watts NB, Manson JE. Osteoporosis and fracture risk evaluation and management: Shared decision making in clinical practice. *JAMA* 2017; 317: 253-4.
- 3. Wang Y, Tao Y, Hyman ME, Li J, Chen Y. Osteoporosis in China. *Osteoporos Int* 2009; 20: 1651-62.
- Lund CA, Møller AM, Wetterslev J, Lundstrøm LH. Organizational factors and long-term mortality after hip fracture surgery. A cohort study of 6143 consecutive patients undergoing hip fracture surgery. *PLoS One* 2014; 9 : e99308.
- Dyer SM, Crotty M, Fairhall N, Magaziner J, Beaupre LA, Cameron ID, *et al.* A critical review of the long-term disability outcomes following hip fracture. *BMC Geriatr* 2016; *16*: 158.
- Tai V, Leung W, Grey A, Reid IR, Bolland MJ. Calcium intake and bone mineral density: Systematic review and metaanalysis. *BMJ* 2015; *351* : h4183.
- Reid IR, Bolland MJ. Calcium and/or vitamin D supplementation for the prevention of fragility fractures: who needs it? *Nutrients* 2020; *12*: 1011.
- Khan M, Jose A, Sharma S. Physiology, Parathyroid Hormone. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
- Bolland MJ, Leung W, Tai V, Bastin S, Gamble GD, Grey A, et al. Calcium intake and risk of fracture: Systematic review. BMJ 2015; 351 : h4580.
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Med* 2009; 6 : e1000097.
- Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan – A web and mobile app for systematic reviews. Syst Rev 2016; 5: 210.
- Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editors. Cochrane handbook for systematic reviews of interventions, 2<sup>nd</sup> ed. Chichester (UK): John Wiley & Sons; 2019.
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, *et al.* The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011; 343 : d5928.

- Zhao JG, Zeng XT, Wang J, Liu L. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: A systematic review and meta-analysis. *JAMA* 2017; *318* : 2466-82.
- Luo D, Liu X, Du J, Liu J, Chen X, Zhou P, et al. Endoscopic transgastric versus surgical approach for infected necrotizing pancreatitis: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech 2019; 29: 141-9.
- 16. JacksDeeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. *Stat Med* 2002; *21* : 1575-600.
- 17. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 7:177-88.
- Hansson T, Roos B. The effect of fluoride and calcium on spinal bone mineral content: a controlled, prospective (3 years) study. *Calcif Tissue Int* 1987; 40: 315-7.
- Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993; 328 : 460-4.
- Recker RR, Hinders S, Davies KM, Heaney RP, Stegman MR, Lappe JM, *et al.* Correcting calcium nutritional deficiency prevents spine fractures in elderly women. *J Bone Miner Res* 1996; *11*: 1961-6.
- Peacock M, Liu G, Carey M, McClintock R, Ambrosius W, Hui S, *et al.* Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. *J Clin Endocrinol Metab* 2000; *85* : 3011-9.
- Avenell A, Grant AM, McGee M, McPherson G, Campbell MK, McGee MA. The effects of an open design on trial participant recruitment, compliance and retention—a randomized controlled trial comparison with a blinded, placebo-controlled design. *Clin Trials* 2004; *1*:490-8.
- 23. Harwood RH, Sahota O, Gaynor K, Masud T, Hosking DJ; Nottingham Neck of Femur (NONOF) Study. A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: the Nottingham Neck of Femur (NONOF) study. *Age Ageing* 2004; 33 : 45-51.
- 24. Porthouse J, Cockayne S, King C, Saxon L, Steele E, Aspray T, *et al.* Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. *BMJ* 2005; *330* : 1003.
- 25. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, *et al.* Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium or vitamin D, RECORD): a randomised placebo-controlled trial. *Lancet* 2005; 365 : 1621-8.
- Prince RL, Devine A, Dhaliwal SS, Dick IM. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebocontrolled trial in elderly women. *Arch Intern Med* 2006; *166*: 869-75.

- Reid IR, Mason B, Horne A, Ames R, Reid HE, Bava U, et al. Randomized controlled trial of calcium in healthy older women. Am J Med 2006; 119: 777-85.
- Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, *et al.* Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. *N Engl J Med* 2006; *354* : 669-83.
- Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women—a populationbased, randomized, double-blind, placebo-controlled trial. *Rheumatology (Oxford)* 2007; 46 : 1852-7.
- Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, *et al.* Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. *JAMA* 2010; *303* : 1815-22.
- Salovaara K, Tuppurainen M, Kärkkäin M, Rikkonen T, Sandini L, Sirola J, *et al.* Effect of vitamin D(3) and calcium on fracture risk in 65- to 71-year-old women: a populationbased 3-year randomized, controlled trial—the OSTPRE-FPS. *J Bone Miner Res* 2010; 25 : 1487-95.
- 32. Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield J, *et al.* Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. *Diabetologia*. 2012; 55: 36-45.
- 33. Hin H, Tomson J, Newman C, Kurien R, Lay M, Cox J, et al. Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care. Osteoporos Int 2017; 28 : 841-51.
- 34. Khaw KT, Stewart AW, Waayer D, Lawes CM, Toop L, Camargo CA, et al. Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial. Lancet Diabetes Endocrinol 2017; 5: 438-47.

- 35. Xue Y, Hu Y, Wang O, Wang C, Han G, Shen Q, et al. Effects of enhanced exercise and combined vitamin D and calcium supplementation on muscle strength and fracture risk in postmenopausal Chinese women. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2017; 39: 345-51.
- 36. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis. *Lancet* 2007; 370 : 657-66.
- Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, *et al*. A pooled analysis of vitamin D dose requirements for fracture prevention. *N Engl J Med* 2012; *367* : 40-9.
- Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, *et al.* Vitamin D3 and calcium to prevent hip fractures in elderly women. *N Engl J Med* 1992; 327:1637-42.
- Bergman GJ, Fan T, McFetridge JT, Sen SS. Efficacy of vitamin D3 supplementation in preventing fractures in elderly women: A meta-analysis. *Curr Med Res Opin* 2010; 26: 1193-201.
- Avenell A, Gillespie WJ, Gillespie LD, O'Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. *Cochrane Database Syst Rev* 2005; 3 : CD000227.
- Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. *Lancet Diabetes Endocrinol* 2014; 2: 307-20.
- Jackson C, Gaugris S, Sen SS, Hosking D. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: A meta-analysis. *QJM* 2007; *100*: 185-92.
- LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, *et al.* Supplmental vitamin D and incident fractures in midlife and older adults. *N Engl J Med* 2022; *387* : 299-309.

For correspondence: Dr Manmeet Kaur, Department of Pathology, All India Institute of Medical Sciences, Mandi Dabwali Road, Bathinda 151 001, Punjab, India e-mail: puniamanmeet@gmail.com



Supplementary Fig. 1. Risk of bias table for included trials.



Supplementary Fig. 2. Risk of bias summary for included trials.



Supplementary Fig. 3. Funnel plot for publication Bias assessment.

## **Supplementary Material**

## Search strategy in database

## PUBMED:

#1 "calcium" [MeSH Terms] OR "calcium" [All Fields]

#2 "vitamin d"[MeSH Terms] OR "vitamin d"[All Fields] OR "ergocalciferols"[MeSH Terms] OR "ergocalciferols"[All Fields]

#3 "fractures, bone"[MeSH Terms] OR ("fractures"[All Fields] AND "bone"[All Fields]) OR "bone fractures"[All Fields] OR "fracture"[All Fields]

#4trial"[Title/Abstract]OR "randomised trial"[Title/Abstract]OR "randomised controlled trial"[Title/Abstract]

#5 #1 or #2

#6 #3 and #5

#7 #4 and #6

# EMBASE:

#1 'calcium'/exp OR calcium

- #2 'vitamin d'/exp OR 'vitamin d'
- #3 'fracture'/exp OR fracture

#4 [cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim

#5 #1 or #2

#6 #3 and 5

#7 #4 and #6

COCHRANE:

#1 calcium:ti,ab,kw

#2 vitamin d:ti,ab,kw

#3 fracture:ti,ab,kw

#4 #1 or #2

#5 #3 and #4

	Supplementary Table: List of	excluded trials and reasons for the same
Trail excluded	Year of publication	Reason for exclusion
Inkovaara <i>et al</i> <sup>1</sup>	1983	Fracture data not reported
Lips <i>et al</i> <sup>2</sup>	1996	Fracture data not reported
Dawson-Hughes et al <sup>3</sup>	1997	Fracture data not reported
Riggs et al <sup>4</sup>	1998	Fracture data not reported
Ruml <i>et al</i> <sup>5</sup>	1998	Fracture data not reported
Baron <i>et al</i> <sup>6</sup>	1999	Fracture data not reported
Trivedi et al <sup>7</sup>	2003	Fracture data not reported
Pfeifer et al <sup>8</sup>	2009	Trial did not include no treatment or placebo group
Bischoff-Ferrari et al9	2010	Trial did not include no treatment or placebo group
Witham <i>et al</i> <sup>10</sup>	2010	Trial did not include no treatment or placebo group
Mitri et al <sup>11</sup>	2011	Fracture data not reported
Sambrook <i>et al</i> <sup>12</sup>	2012	Trial included mandatory sunlight exposure in one of the groups
Schaller <i>et al</i> <sup>13</sup>	2012	Fracture data not reported
Rossini et al <sup>14</sup>	2012	Trial is non-randomized
Gendenneing et al <sup>15</sup>	2012	Fracture data not reported
Aloia <i>et al</i> <sup>16</sup>	2013	Fracture data not reported
Witham <i>et al</i> <sup>17</sup>	2013	Fracture data not reported
Tella <i>et al</i> <sup>18</sup>	2014	Placebo group not included
Takano <i>et al</i> <sup>19</sup>	2014	Placebo or no treatment group not included
REVITAHIP trail et al <sup>20</sup>	2014	Placebo or no treatment group not included
Massart <i>et al</i> <sup>21</sup>	2014	Fracture data not reported
Martineau et al <sup>22</sup>	2015	Fracture data not reported
Wang <i>et al</i> <sup>23</sup>	2015	Multivitamin tablets were administered in the experimental group
Rolighed et al <sup>24</sup>	2015	Fracture data not reported
Uusi-Rasi et al <sup>25</sup>	2015	Fracture data not reported
Liu et al <sup>26</sup>	2015	Fracture data not reported
Schwetz et al <sup>27</sup>	2017	Fracture data not reported
Laiz <i>et al</i> <sup>28</sup>	2017	Exercise was included in the intervention group
Pop et al <sup>29</sup>	2017	Placebo or no treatment group not included
Leblanc <i>et al</i> <sup>30</sup>	2018	Ongoing trial
Joseph <i>et al</i> <sup>31</sup>	2018	Ongoing trial
DO-HEALTH <sup>32</sup>	2019	Ongoing trial

## References

- 1. Inkovaara J, Gothoni G, Halttula R, Heikinheimo R, Tokola O. Calcium, vitamin D and anabolic steroid in treatment of aged bones: double-blind placebo-controlled long-term clinical trial. *Age Ageing* 1983; *12* : 124-130.
- 2. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. *Ann Intern Med* 1996; *124* : 400-6.
- 3. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med* 1997; *337* : 670-6.
- 4. Riggs BL, O'Fallon WM, Muhs J, O'Connor MK, Kumar R, Melton LJ III. Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. *J Bone Miner Res* 1998; *13* : 168-74.

- 5. Ruml LA, Sakhaee K, Peterson R, Adams-Huet B, Pak CY. The effect of calcium citrate on bone density in the early and midpostmenopausal period: a randomized placebo-controlled study. *Am J Ther* 1999; 6: 303-11.
- 6. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS, *et al.* Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. *N Engl J Med* 1999; *340* : 101-7.
- 7. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ* 2003; *326* : 469
- 8. Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. *Osteoporos Int* 2009; 20: 315-22.
- Bischoff-Ferrari HA, Dawson-Hughes B, Platz A, Orav EJ, Stähelin HB, Willett WC, et al. Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial. Arch Intern Med 2010; 170: 813-20.
- Witham MD, Crighton LJ, Gillespie ND, Struthers AD, McMurdo ME. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. *Circ Heart Fail* 2010; 3: 195-201.
- Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic beta cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. *American J Clin Nutr* 2011; 94 : 486-94.
- 12. Sambrook PN, Cameron ID, Chen JS, Cumming RG, Durvasula S, Herrmann M, *et al.* Does increased sunlight exposure work as a strategy to improve vitamin D status in the elderly: a cluster randomised controlled trial. *Osteoporos Int* 2012; *23* : 615-24.
- 13. Schaller F, Sidelnikov E, Theiler R, Egli A, Staehelin HB, Dick W, *et al.* Mild to moderate cognitive impairment is a major risk factor for mortality and nursing home admission in the first year after hip fracture. *Bone* 2012; *51* : 347-52.
- 14. Rossini M, Gatti D, Viapiana O, Fracassi E, Idolazzi L, Zanoni S, *et al.* Short-term effects on bone turnover markers of a single high dose of oral vitamin D? *Clin Endocrinol Metab* 2012; 97 : E622-6.
- 15. Glendenning P, Zhu K, Inderjeeth C, Howat P, Lewis JR, Prince RL. Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: A randomized controlled trial. *J Bone Miner Res* 2012; 27: 170-6.
- Aloia JF, Dhaliwal R, Shieh A, Mikhail M, Islam S, Yeh JK. Calcium and vitamin D supplementation in postmenopausal women. J Clin Endocrinol Metab 2013; 98 : E1702-9.
- Witham MD, Price RJ, Struthers AD, Donnan PT, Messow CM, Ford I, *et al.* Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. *JAMA Intern Med* 2013; *173*: 1672-9.
- Tella H, Gallagher JC, Smith L. Effect of vitamin D supplementation on BMD in young and elderly caucasian and African American women: two randomized, placebo controlled trials. Endocrine reviews. Conference: 96th annual meeting and expo of the endocrine society, ENDO 2014. Chicago, IL united states. 2014; 35 (no pagination).
- Takano T, Kondo S, Saito H, Matsumoto T, Eldecalcitol Study Group. Relationship between the effect of eldecalcitol and serum 25(OH) D level. J Steroid Biochem Mol Biol 2014; 144 Pt A : 124-7.
- 20. Mak JC, Klein LA, Finnegan T, Mason RS, Cameron ID. An initial loading-dose vitamin D versus placebo after hip fracture surgery: baseline characteristics of a randomized controlled trial (REVITAHIP). *BMC Geriatrics* 2014; *14* : 101.
- 21. Massart A, Debelle FD, Racapé J, Gervy C, Husson C, Dhaene M, *et al.* Biochemical parameters after Cholecalciferol repletion in hemodialysis: Results from the vitadial randomized trial. *Am J Kidney Dis* 2014; *64* : 696-705.
- Martineau AR, Hanifa Y, Hooper RL, Witt KD, Patel M, Syed A. Increased risk of upper respiratory infection with addition of intermittent bolus-dose vitamin D supplementation to a daily low-dose regimen [Abstract]. *Thorax* 2013; 68 (Suppl 3): A64 [s123].
- Wang SM, Yin LY, Zhang Y, Fan JH, Chang IJ, Dawsey SM, et al. Multivitamin and mineral supplementation is associated with the reduction of fracture risk and hospitalization rate in Chinese adult males: a randomized controlled study. J Bone Miner Metab 2015; 33 : 294-302.
- Rolighed L, Rejnmark L, Sikjaer T, Heickendorff L, Vestergaard P, Mosekilde L, *et al.* No beneficial effects of vitamin D supplementation on muscle function or quality of life in primary hyperparathyroidism: Results from a randomized controlled trial. *Eur J Endocrin* 2015; *172*: 609-17.
- Uusi-Rasi K, Patil R, Karinkanta S, Kannus P, Tokola K, Lamberg-Allardt C, *et al.* Exercise and vitamin D in fall prevention among older women: a randomized clinical trial. *JAMA Intern Med* 2015; 175 : 703-11.
- Liu BX, Chen SP, Li YD, Wang J, Zhang B, Lin Y, *et al.* The effect of the modified eighth section of eight-section brocade on osteoporosis in postmenopausal women: A prospective randomized trial. Medicine (Baltimore) 2015; 94 : 991.
- Laiz A, Malouf J, Marin A, Longobardi V, de Caso J, Farrerons J, *et al.* Impact of 3-monthly vitamin D supplementation plus exercise on survival after surgery for osteoporotic hip fracture in adult patients over 50 years: A pragmatic randomized, partially blinded, controlled trial. *J Nutr Health Aging* 2017; 21: 413-20.

- 29. Pop LC SD, Schneider SH, Schlussel Y, Stahl T, Gordon C, Wang X, *et al.* Three doses of vitamin D, bone mineral density, and geometry in older women during modest weight control in a 1-year randomized controlled trial. *Osteoporos Int* 2016; 28 : 377-88.
- LeBlanc E, Chou R, Zakher B, Daeges M, Pappas M. Screening for Vitamin D Deficiency: Systematic Review for the U.S. Preventive Services Task Force Recommendation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Nov. Report No.: 13-05183-EF-1.
- Joseph P, Pais P, Dans AL, Bosch J, Xavier D, Lopez-Jaramillo P, et al. The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. Am Heart J 2018; 206 : 72-9.
- Bischoff-Ferrari HA, de Godoi Rezende Costa Molino C, Rival S, Vellas B, Rizzoli R, Kressig RW, et al. DO-HEALTH: Vitamin D3 -Omega-3 - Home exercise - Healthy aging and longevity trial - Design of a multinational clinical trial on healthy aging among European seniors. Contemp Clin Trials 2021; 100 : 106124.